Arsenal Biosciences
Arsenal Biosciences raises $325M Series C
Quick Facts
Arsenal Biosciences: Series C Funding Round
Arsenal Biosciences has successfully raised $325M in Series C funding.
Company Overview
Cell therapy company developing programmable T-cell therapies for solid tumors
Funding Details
The Series C round was led by Arch Venture Partners, with participation from T. Rowe Price Associates.
Company Information
- Headquarters: South San Francisco, CA
- Founded: 2019
- Employees: 150+
- Category: HealthTech
Investment
Arsenal Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Arch Venture Partners: Verified investor in Series C
- T. Rowe Price Associates: Verified investor in Series C
Key Investors
About the Author
Related Company Reports
AccelerateStack Platform raises $75M Series C at $226M valuation
AccelerateStack Platform secures $75M in Series C funding led by Intel Capital, reaching $226M valuation as it accelerates growth in the healthtech sector.
DermaSensor raises $16M Series B at $85M valuation
DermaSensor raises $16M in Series B at $85M valuation. AI-powered skin cancer screening device for early detection...
Devoted Health Partners Headquarters - Office Location & Address
Discover Devoted Health Partners's headquarters at 100 2nd Ave, Waltham, MA 02451. Medicare Advantage insurance. Learn about the office facilities and work environment.
